ArticleMediators of inflammation2016
Activation of Melanocortin Receptors MC 1 and MC 5 Attenuates Retinal Damage in Experimental Diabetic Retinopathy.
Article in Mediators of inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity?World journal of gastroenterology · 2024Trial
- Functional polymorphisms in pigmentation-related genesBiochemistry and biophysics reports · 2026Article
- Melanocortin 5 receptor signaling protects against podocyte injury in proteinuric glomerulopathies.Kidney international · 2025Article
- Alpha-Melanocyte-Stimulating Hormone Maintains Retinal Homeostasis after Ischemia/Reperfusion.Biomolecules · 2024Article
- Therapeutic Effects of Stimulating the Melanocortin Pathway in Regulating Ocular Inflammation and Cell Death.Biomolecules · 2024Review
- Therapeutic Potential of Fingolimod in Diabetes Mellitus and Its Chronic Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy.Frontiers in pharmacology · 2024Article
- Diabetic vascular diseases: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2023Review
- Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina.International journal of molecular sciences · 2023Article
- Identifying missing pieces in color vision defects: a genome-wide association study in Silk Road populations.Frontiers in genetics · 2023Article
- Melanocortin receptor agonists suppress experimental autoimmune uveitis.Experimental eye research · 2022Article
- Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats With Puromycin Aminonucleoside Nephrosis.Frontiers in physiology · 2022Article
- Sex and Age-Related Differences in Neuroinflammation and Apoptosis inInternational journal of molecular sciences · 2021Article
- The Role of the Effects of Endoplasmic Reticulum Stress on NLRP3 Inflammasome in Diabetes.Frontiers in cell and developmental biology · 2021Review
- Corrigendum to "Activation of Melanocortin Receptors MCMediators of inflammation · 2021Article
- Autophagy: A Novel Pharmacological Target in Diabetic Retinopathy.Frontiers in pharmacology · 2021Review
- Melanocortin 5 receptor signaling pathway in health and disease.Cellular and molecular life sciences : CMLS · 2020Review
- Changes in Retinal Structure and Ultrastructure in the Aged Mice Correlate With Differences in the Expression of Selected Retinal miRNAs.Frontiers in pharmacology · 2020Article
- Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach.British journal of pharmacology · 2019Article
- CCL20-CCR6 axis modulated traumatic brain injury-induced visual pathologies.Journal of neuroinflammation · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We hypothesize that melanocortin receptors (MC) could activate tissue protective circuit in a model of streptozotocin- (STZ-) induced diabetic retinopathy (DR) in mice. At 12-16 weeks after diabetes induction, fluorescein angiography (FAG) revealed an approximate incidence of 80% microvascular changes, typical of DR, in the animals, without signs of vascular leakage. Occludin progressively decreased in the retina of mice developing retinopathy. qPCR of murine retina revealed expression of two MC receptors, Mc1r and Mc5r. The intravitreal injection (5 μL) of the selective MC1 small molecule agonist BMS-470539 (33 μmol) and the MC5 peptidomimetic agonist PG-901 (7.32 nM) elicited significant protection with regular course and caliber of retinal vessels, as quantified at weeks 12 and 16 after diabetes induction. Mouse retina homogenate settings indicated an augmented release of IL-1α, IL-1β, IL-6, MIP-1α, MIP-2α, MIP-3α, and VEGF from diabetic compared to nondiabetic mice. Application of PG20N or AGRP and MC5 and MC1 antagonist, respectively, augmented the release of cytokines, while the agonists BMS-470539 and PG-901 almost restored normal pattern of these mediators back to nondiabetic values. Similar changes were quantified with respect to Ki-67 staining. Finally, application of MC3-MC4 agonist/antagonists resulted to be inactive with respect to all parameters under assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.